Technology

Lundbeck Maintains Development Plans for AprilBio Co.,Ltd.’s ‘APB-A1’… Concerns Over Technology Return Eased

KIM SAE-MI
2026-11-17 07:42:03
[Edaily Reporter KIM SAE-MI ] Danish pharmaceutical company Lundbeck has once again emphasized the potential for multi-indication expansion of its new drug candidate “APB-A1” (Lu AG22515), which it licensed from AprilBio Co.,Ltd.(397030). Although concerns had previously been raised about the technology being returned due to clinical issues related to thyroid-associated ophthalmopathy (TED), those concerns appear to be easing as Lundbeck has retained APB-A1 in its development pipeline in its third-quarter investor relations (IR) materials.

Lundbeck continues to maintain “APB-A1” (Lu AG22515) in its development pipeline in the third quarter of this year. (Source: Lundbeck)

Three Months Since TED Clinical Trial Halt… Lundbeck Maintains ‘APB-A1’ in Pipeline
According to the biotech industry on the 12th, Lundbeck revealed in its third-quarter earnings IR materials released on the 11th that it is still maintaining APB-A1 in its development pipeline.

Lundbeck cited the following as APB-A1’s competitive advantages: △ a unique mode of action △ confirmed proof of mechanism △ strong biomarkers △ potential for expansion into multiple indications.

In particular, the company highlighted the potential for the CD40 ligand (CD40L) blockade mechanism to be applied to various neuroimmunological diseases. Multiple sclerosis (MS), neuromyelitis optica (NMO), and myasthenia gravis (MG) were cited as potential areas for development. These are diseases in which damage to the nervous system occurs due to immune system dysfunction.

However, this information does not differ significantly from the second-quarter investor relations (IR) materials released last August, nor have any new follow-up indications or clinical development schedules been finalized. Nevertheless, it is considered significant that APB-A1 remains in Lundbeck’s official development pipeline approximately three months after the announcement of the TED clinical trial results.

An AprilBio Co.,Ltd. official emphasized, “Although subsequent indications have not yet been finalized, if a decision to return the technology had been made, that slide would have been removed,” adding, “This means that even though we haven’t announced any indications, development has not yet been halted.”

TED Efficacy Fell Short of Expectations… But New Indications Being Explored
APB-A1 is a CD40L inhibitor developed by AprilBio Co.,Ltd. using its proprietary long-acting biopharmaceutical platform, “SAFA.” In 2021, AprilBio Co.,Ltd. licensed APB-A1 to Lundbeck in a deal worth up to $448 million (537 billion won), including an upfront payment of $16 million (approximately 19 billion won).

Lundbeck had been developing APB-A1 as a treatment for TED, but in August, based on Phase 1b clinical trial results, the company decided not to continue development for that indication. This was because, although pharmacological activity—such as a reduction in autoantibodies in patients—and the mechanism of action were confirmed, they did not translate into the level of clinical therapeutic efficacy that had been anticipated.

However, the company explains that this decision does not imply that the mechanism of action of APB-A1 itself is ineffective. Since immunological changes resulting from CD40L blockade have been confirmed, there remains potential to verify its therapeutic efficacy in other autoimmune or neuroimmune diseases.

Lundbeck also stated in its first-half earnings report last August, “The safety and tolerability confirmed to date support the continued evaluation of APB-A1,” adding, “We are determining the direction of follow-up development, such as exploring other indications where the CD40-CD40L mechanism is more directly involved.”

AprilBio Co.,Ltd. Focuses on Three New Drugs… Doubts Remain About SAFA’s Competitiveness
On the 9th, at its first-ever Research and Development (R&D) Day, AprilBio Co.,Ltd. unveiled three new drug candidates utilizing its next-generation platform “REMAP” and its early-stage technology transfer strategy. At the time, AprilBio Co.,Ltd. CEO Cha Sang-hoon remarked, “We determined that it is more important to seek new growth opportunities based on the new drug development capabilities we have accumulated over the years, rather than staking the company’s entire future on a single platform called SAFA.”

Cha Sang-hoon, CEO of AprilBio Co.,Ltd. (Photo: ReporterKIM SAE-MI )

Some observers raised doubts about whether the SAFA platform’s competitiveness had weakened, noting that the company provided relatively little explanation regarding its existing technology export pipeline and the SAFA platform.

In response, an AprilBio Co.,Ltd. official stated, “(Rather than being an issue with the existing platform), the CD40L target did not produce the therapeutic effects TED had anticipated,” adding, “We cannot conclude that the reduced efficacy was due to the application of the SAFA platform.”

The spokesperson continued, “The original purpose of this R&D Day was to explain how we plan to utilize the funds secured following the large-scale investment round and to introduce new pipelines that had been lacking until now,” emphasizing, “We did not focus on new pipelines because of uncertainties surrounding our existing technology export assets.”

AprilBio Co.,Ltd. secured 346.8 billion won in investment this year from TKG Group and IMM Investment, securing approximately 430 billion won in cash liquidity, including existing funds. Building on this, the company is pursuing its “AprilBio 2.0” strategy, which involves not only developing new drugs using its proprietary platform but also concurrently pursuing external technology acquisition, joint development, and the establishment of NewCos.

CEO Cha stated, “New drug development inherently involves uncertainty. No matter how solid the scientific basis may be, there is always a possibility of failure in clinical trials,” adding, “We will prove our track record step by step through data and execution.”

Economy

Corporation

IT·Science

Economy

[37th SRE][Survey] How Did the 37th SRE Go?

Edaily’s annual “Survey of Credit Ratings by Edaily” (SRE), which has been conducted among corporate bond market experts since 2005, has reached its 37th edition. The SRE is a regular survey in which …
2026-11-17 08:02:03

Corporation

[Exclusive] Company Hints at Legal Battle with Largest Shareholder… Key Issue: Abolition of Supermajority Voting [OSCOTEC Inc. Dispute, Part 2]

September 22. With the Chuseok holiday just two days away, many people were buzzing with anticipation for the long weekend. However, the largest shareholder, standing in the public service office of t…
2026-11-17 08:01:02

IT·Science

HyundaiAutoever Named “Outstanding Honorary Company” for Shared Growth

Hyundai AutoEver ( HyundaiAutoever(307950)) announced on the 17th that it has been selected as a “Top Honorary Company” after receiving the highest rating for the third consecutive year in the “2026 S…
2026-11-17 07:55:28